Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCT4BA)

Drug Name

DMUC-5754A Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Fallopian tube cancer	2C74	Phase 1	[1]
Ovarian cancer	2C73	Phase 1	[1]
Peritoneal cancer	2C51.Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ovarian carcinoma antigen CA125 (MUC16)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oregovomab	DM06KRC	Ovarian cancer	2C73	Phase 3	[3]
Abagovomab	DMZ0T24	Ovarian cancer	2C73	Phase 2/3	[4]
REGN4018	DM7LOSK	Ovarian cancer	2C73	Phase 1/2	[5]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[6]
JCAR020	DM1T8KN	Ovarian cancer	2C73	Phase 1	[7]
PRGN-3005	DMCUE71	Refractory hematologic malignancy	2A85.5	Phase 1	[8]
RG7458	DMW87YE	Ovarian cancer	2C73	Discontinued in Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ovarian carcinoma antigen CA125 (MUC16)	TTC1PS3	MUC16_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01335958) Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
2	Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32.
3	MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
4	Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.
5	A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
6	ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Clinical pipeline report, company report or official report of Precigen.
9	Phase I clinical trail of RG7458 for treating Ovarian cancer. Genentech Inc.